Korean J Gastroenterol.  2022 Mar;79(3):138-139. 10.4166/kjg.2022.028.

The Phase 2 Study to Evaluate Efficacy and Safety of Lanifibranor in Patients with Nonalcoholic Steatohepatitis: Back in the Spotlight?

• Lee SH

• KMID: 2527483
• DOI: http://doi.org/10.4166/kjg.2022.028

Reference

1. Kang SH, Lee HW, Yoo JJ, et al. 2021; KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 27:363–401. DOI: 10.3350/cmh.2021.0178. PMID: 34154309. PMCID: PMC8273632.

2. Sanyal AJ, Chalasani N, Kowdley KV, et al. 2010; Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 362:1675–1685. DOI: 10.1056/NEJMoa0907929. PMID: 20427778. PMCID: PMC2928471.

3. Ratziu V, Harrison SA, Francque S, et al. 2016; Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 150:1147–1159.e5. DOI: 10.1053/j.gastro.2016.01.038. PMID: 26874076.

4. Anania FA, Dimick-Santos L, Mehta R, Toerner J, Beitz J. 2021; Nonalcoholic steatohepatitis: current thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration. Hepatology. 73:2023–2027. DOI: 10.1002/hep.31687. PMID: 33340111.

5. Wilding JPH, Batterham RL, Calanna S, et al. 2021; Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 384:989. DOI: 10.1056/NEJMoa2032183. PMID: 33567185.

6. Newsome PN, Buchholtz K, Cusi K, et al. 2021; A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 384:1113–1124. DOI: 10.1056/NEJMoa2028395. PMID: 33185364.